MEI Pharma Inc

MEI Pharma Inc a latestage pharmaceutical company focuses on the development and commercialization of various therapies for the treatment of cancer The company develops Zandelisib an oral phosphatidylinositol 3kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsedrefractory follicular lymphoma as well as in Phase Ib multiarm trial to treat Bcell malignancies and Voruciclib an oral cyclindependent kinase 9 inhibitor which is in Phase Ib clinical trial for acute myeloid leukemia and Bcell malignancies It also develops ME344 a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer and Pracinostat an oral available histone deacetylase inhibitor which is in Phase II clinical trial to treat patients with myelodysplastic syndrome MEI Pharma Inc has a license development and commercialization agreement with Kyowa Kirin Company a clinical collaboration with BeiGene Ltd a license development manufacturing and commercialization agreement with Helsinn Healthcare SA and a license agreement with Presage Biosciences Inc The company was formerly known as Marshall Edwards Inc and changed its name to MEI Pharma Inc in July 2012 MEI Pharma Inc was incorporated in 2000 and is headquartered in San Diego California